KUVAN Drug Patent Profile

Which patents cover Kuvan, and what generic alternatives are available?

Kuvan is a drug marketed by Biomarin Pharm and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kuvan

A generic version of KUVAN was approved as sapropterin dihydrochloride by PH HEALTH on May 10^th, 2019.

Summary for KUVAN

International Patents:	16
US Patents:	3
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KUVAN

Paragraph IV (Patent) Challenges for KUVAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KUVAN	Powder for Oral Solution	sapropterin dihydrochloride	500 mg per packet	205065	1	2017-02-23
KUVAN	Powder for Oral Solution	sapropterin dihydrochloride	100 mg per packet	205065	1	2015-11-09
KUVAN	Tablets	sapropterin dihydrochloride	100 mg	022181	1	2014-06-05

US Patents and Regulatory Information for KUVAN

KUVAN is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-001	Dec 19, 2013	AB	RX	Yes	Yes	9,216,178*PED				Y
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	TABLET;ORAL	022181-001	Dec 13, 2007	AB	RX	Yes	Yes	8,003,126*PED				Y
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-002	Oct 27, 2015	AB	RX	Yes	Yes	9,216,178*PED				Y
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	TABLET;ORAL	022181-001	Dec 13, 2007	AB	RX	Yes	Yes	7,566,462*PED				Y

International Patents for KUVAN

When does loss-of-exclusivity occur for KUVAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KUVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	052238	FORMULACION DE TABLETAS ESTABLES
Australia	2005306686	Stable tablet formulation of tetrahydrobiopterin
Brazil	PI0517088	formulação de comprimido estável
Canada	2581814	FORMULE STABLE DE COMPRIMES (STABLE TABLET FORMULATION OF TETRAHYDROBIOPTERIN)
China	101132776	Stable tablet formulation of tetrahydrobiopterin
European Patent Office	1845952	FORMULE STABLE DE COMPRIMES DE TETRAHYDROBIOPTERINE (STABLE TABLET FORMULATION OF TETRAHYDROBIOPTERIN)
European Patent Office	2436379	Formule de comprimé stable (Stable tablet formulation)

Investment Scenario, Market Dynamics, and Financial Trajectory for KUVAN

Last updated: February 3, 2026

Executive Summary

KUVAN (lumasiran), developed by Alnylam Pharmaceuticals, is a gene-silencing therapy approved by the FDA in 2020 for the treatment of primary hyperoxaluria type 1 (PH1). This rare genetic disorder results in excessive oxalate production, leading to kidney stones, nephrocalcinosis, and potential renal failure. The drug's unique RNA interference (RNAi) mechanism positions it within the fast-growing field of targeted genetic therapies.

Currently, the global orphan drug market and the niche for metabolic rare disease treatments present significant growth opportunities. However, challenges such as high development costs, limited patient populations, and pricing pressures influence KUVAN's financial profile.

This analysis provides a comprehensive overview of KUVAN's current market landscape, projected financial trajectory, competitive environment, and investment risk profile, offering strategic insights for industry stakeholders.

---

Market Overview and Disease Epidemiology

Parameter	Details
Disease	Primary Hyperoxaluria Type 1 (PH1)
Global Prevalence (Estimated)	1-3 per million population (approx. 1000-2000 patients globally)
Geographic Distribution	Higher prevalence in North America and Europe; variable in other regions
Diagnosis Timing	Often diagnosed late due to nonspecific symptoms; early detection improves outcomes
Standard of Care Prior to KUVAN	High-flux dialysis, nephrectomy, liver-kidney transplantation

Epidemiology Breakdown

Region	Estimated Patients	Market Penetration (%)	Potential Market Size (Patients)
North America	700-900	10-15	70-135
Europe	300-500	10-15	30-75
Rest of World	0-600	Low	0-40

Note: The low diagnosis rate markedly limits total addressable market (TAM), despite high unmet medical need.

---

Current Market Dynamics

KUVAN’s Regulatory and Commercial Milestones

Milestone	Date	Impact
FDA Approval	August 2020	Validated RNAi technology for PH1
EMA Approval	December 2020	Expanded market access
Commercial Launch (US)	Q4 2020	Secured early access, establishing payer agreements
Market Penetration (2022)	~20% of diagnosed patients	Reflects cautious uptake, reimbursement challenges

Market Penetration Challenges

• Limited awareness: PH1 diagnosis often delayed.
• Cost barriers: Approximate annual treatment cost ~$450,000 in U.S.
• Reimbursement policies: Negotiations ongoing, impacting sales velocity.
• Competitive landscape: No direct gene-silencing competitors approved; some pipeline candidates exist.

Competitor and Pipeline Overview

Product	Developer	Mechanism	Development Status
Lumasiran (KUVAN)	Alnylam Pharmaceuticals	RNAi	Approved for PH1
Nedosiran	Dicerna (via Roche partnership)	RNAi	Phase 3; potential competitor
Gene therapy approaches	Multiple (preclinical)	Gene correction	Preliminary stages; potential future competition

---

Financial Trajectory of KUVAN

Revenue Growth Projections (2023-2030)

Year	Estimated Revenue (USD Million)	Assumptions
2023	125	Launch growth, expanding diagnosed population, reimbursement gains
2024	180	Increased penetration, expanded geographic coverage
2025	250	Broader adoption, initial pipeline contributions
2026	330	Market penetration plateau, new patient identification processes
2027	400	Steady growth, potential expansion into related indications
2030	550	Reach of 15-20% market penetration, improved diagnosis rates

Cost and Profitability Analysis

Parameter	Details
Direct Production Cost (per dose)	Estimated $50,000–$70,000
Gross Margin	~85% based on pricing and manufacturing costs
R&D Investment (annual)	Approx. $200 million (for pipeline & improvements)
Operating Expenses	Estimated $150–200 million annually
Break-even Point	Expected around 2024–2025, contingent on sales volume

Patent and IP Landscape

| Patent Expiry | 2028–2030 | Patent life extension through method patents or secondary filings expected. | | Key Patents | IP related to siRNA sequences, delivery methods, and composition of matter. |

---

Market Opportunities and Risks

Opportunities

• Growing orphan drug market: CAGR ~10% globally, driven by regulatory incentives and unmet needs.
• Potential label expansion: Early-stage research explores broader indications, increasing TAM.
• Pipeline development: Next-generation RNAi and gene editing therapies may complement or compete.

Risks

• Pricing and reimbursement constraints: Payer resistance could limit uptake.
• Market penetration delays: Due to diagnostic challenges or surgical interventions.
• Pipeline and pipeline competition: Potential biosimilars or alternative gene therapies may impact KUVAN’s dominance.
• Regulatory delays: Additional approvals or label expansions may be hindered by clinical data requirements.

---

Comparative Analysis with Similar Orphan Drugs

Drug Name	Indication	Market Launch Year	Peak Sales (USD Million)	Key Features
Spinraza	Spinal muscular atrophy (SMA)	2016	3,000+	First-of-its-kind gene therapy
Lumizyme	Pompe disease	2014	850	Enzyme replacement therapy
Ravicti	Urea cycle disorder	2013	300	Oral ammonia scavenger

Contrast: KUVAN's niche market limits peak sales potential but offers high margins due to rarity and targeted mechanism.

---

Strategic Recommendations for Investors

• Prioritize companies with early pipeline candidates, which may threaten KUVAN's market share.
• Monitor reimbursement policies across key regions to assess market access hurdles.
• Evaluate demographic shifts improving diagnosis rates, thus expanding the accessible patient base.
• Assess pipeline developments, especially gene therapies, that could serve as long-term competition.
• Consider valuation based on discounted cash flow (DCF) models incorporating conservative penetration estimates.

---

Key Takeaways

• KUVAN addresses a rare but serious metabolic disorder with high unmet need, resulting in a niche but potentially lucrative market.
• Revenue growth is expected to accelerate through expanded diagnosis and geographic presence; however, growth is constrained by diagnosis delays, pricing pressures, and competition.
• The financial trajectory indicates peak sales around USD 550 million by 2030, with high margins supporting profitability.
• Competition, notably from pipeline candidates like nedosiran, and policy changes could impact long-term viability.
• Strategic market expansion, инновационный науки, and regulatory navigation are critical for maximizing investment returns.

---

FAQs

1. What is the global market potential for KUVAN?
Estimated to reach approximately USD 550 million annually by 2030, contingent on diagnosis rates, reimbursement policies, and geographic expansion.

2. How does KUVAN compare with emerging RNAi therapies?
Nedosiran and other pipeline RNAi treatments aim to address PH1 and related disorders—potentially acting as direct competitors upon approval with similar mechanisms and market strategies.

3. What are the primary barriers to wider adoption of KUVAN?
Delayed diagnosis, high treatment costs, reimbursement hurdles, and limited awareness restrict rapid market penetration.

4. What is the impact of patent expirations on KUVAN’s finances?
Patent expiry around 2028–2030 could open the door for biosimilar competition, necessitating continued innovation and pipeline development.

5. How significant is the role of gene editing in the future of PH1 treatment?
Gene editing offers potential for curative therapies, but clinical readiness remains years away, making RNAi therapies like KUVAN immediate market focus.

---

References

[1] Alnylam Pharmaceuticals. KUVAN (lumasiran) Prescribing Information. 2020.
[2] Global Market Insights. Orphan Drug Market Size & Trends. 2022.
[3] FDA. Oncology and Rare Disease Approvals. 2020–2022.
[4] ClinicalTrials.gov. Pipeline status for PH1 therapies. 2023.

Note: Data points, estimates, and projections are subject to change in response to evolving clinical, regulatory, and market developments.